Ciprofloxacin Hydrochloride API

Mechanism of Action

The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV (both Type II topoisomerases), which are required for bacterial DNA replication, transcription, repair, and recombination.

Indication

CIPRO is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with the following infections caused by designated, susceptible bacteria and in pediatric patients where indicated:
• Skin and Skin Structure Infections
• Bone and Joint Infections
• Complicated Intra-Abdominal Infections
• Infectious Diarrhea
• Typhoid Fever (Enteric Fever)
• Uncomplicated Cervical and Urethral Gonorrhea
• Inhalational Anthrax post-exposure in adult and pediatric patients
• Plague in adult and pediatric patients
•  Chronic Bacterial Prostatitis
•  Lower Respiratory Tract Infections
o Acute Exacerbation of Chronic Bronchitis
•  Urinary Tract Infections
o Urinary Tract Infections (UTI)
o Acute Uncomplicated Cystitis
o Complicated UTI and Pyelonephritis in Pediatric Patients
•  Acute Sinusitis

Usage
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CIPRO and other antibacterial drugs, CIPRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Ciprofloxacin Hydrochloride API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Ciprofloxacin Hydrochloride API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.